Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 January 2020 | Story Eugene Seegers | Photo Kaleidoscope Studios | Sonia Small
Kaleidoscope - Dr Maria Madiope - New South Campus Principal
Dr Maria Madiope took over the reins of the UFS South Campus at the beginning of January 2020.

The Council of the University of the Free State (UFS) approved the appointment of Dr Maria ‘Marinkie’ Madiope as Principal of the South Campus for Open Distance Learning (ODL) during a meeting held on 20 September 2019. Dr Madiope took over the reins of the UFS South Campus at the beginning of January 2020.

Educator at heart

Educating and empowering others are key aspects of Dr Madiope's life. She has served as the Director for University Teaching and Learning at Unisa since 2015 and takes her role incredibly seriously, achieving a transformative curriculum at the colleges under her care since her appointment.

Dr Madiope holds a PhD in Education from Unisa, with a specialisation in Didactics; her next two degrees where completed at the then RAU, which is today known as the University of Johannesburg: a BEd in 1999, followed by an MEd in 2001, both specialising in Computer-based Instruction. She previously obtained her BA Ed in 1985 and a BEd in 1988 from the University of the North. Her initial training as a teacher was from the Hebron College of Education from 1980-81.

Dr Madiope is also the editor of the only journal in ODL, Progressio, since 2016. Her expertise in E-learning is another of her strong points. Together with her team, Dr Madiope designed and developed the first online course in Curriculum Transformation, which is being piloted at Unisa. Her work has been rewarded with awards such as the Unisa Gender Activism: Advocacy and Promotion of Women’s Rights 2013, Unisa Woman of the Year 2013, and Unisa Best Performer 2013.

Dr Madiope brings with her a wealth of experience to UFS and her vision is to increase access to a wider base of learners with potentially having more African learners enrolled. The first point of call would be to have more learners coming from Lesotho and then the rest of the SADEC region, having the UFS become a leading distance-learning university. One of the key projects that Dr Madiope wishes to tackle is early childhood development. “I believe in educating educators to ensure that they are best equipped to provide the latest and relevant Early childhood and development practices that are on par with the rest of the world,” she says.

Community leader

In addition to being an experienced educator and administrator, Dr Madiope is instrumental in community projects that lie close to her heart. Whether it is large-scale advocacy for women’s rights or her personal involvement in the supply of sanitary towels for schoolgirls as part of a programme to empower the girl child through exposing them to options, it is humbling to watch her compassion in action.

She further intends to strengthen the relationship of the university with TVET Colleges and community colleges by providing mutually beneficial programmes that will up-skill those colleagues by giving them an opportunity to work with experienced UFS staff members. She says, “Reaching out to colleagues in TVET and Community colleges will offer them the opportunity to advance their lecturing and learning programmes, which will only lead to benefiting their learners and South Africa as a whole.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept